2181 Stock Overview
Mabpharm Limited, a biopharmaceutical company, engages in research, development, and production of drugs and biosimilar drugs for cancers and autoimmune diseases in the People’s Republic of China.
Mabpharm Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$0.47|
|52 Week High||HK$0.99|
|52 Week Low||HK$0.34|
|1 Month Change||-4.04%|
|3 Month Change||-15.18%|
|1 Year Change||35.71%|
|3 Year Change||-59.75%|
|5 Year Change||n/a|
|Change since IPO||-60.74%|
Recent News & Updates
Mabpharm (HKG:2181) Is Making Moderate Use Of DebtOct 20
Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn SituationJan 18
Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn SituationOct 07
Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn SituationApr 28
Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?Mar 03
We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn RateJan 27
Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?Dec 09
|2181||HK Biotechs||HK Market|
Return vs Industry: 2181 exceeded the Hong Kong Biotechs industry which returned 3.9% over the past year.
Return vs Market: 2181 exceeded the Hong Kong Market which returned 5.2% over the past year.
|2181 Average Weekly Movement||13.0%|
|Biotechs Industry Average Movement||8.3%|
|Market Average Movement||6.5%|
|10% most volatile stocks in HK Market||14.1%|
|10% least volatile stocks in HK Market||3.2%|
Stable Share Price: 2181 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: 2181's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
Mabpharm Limited, a biopharmaceutical company, engages in research, development, and production of drugs and biosimilar drugs for cancers and autoimmune diseases in the People’s Republic of China. The company’s products under the Phase III clinical trial include CMAB007, a recombinant humanized anti-immunoglobulin E monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for moderate to severe active rheumatoid arthritis; and CMAB807 for osteoporosis indications. It is also developing CMAB819 that is in Phase I clinical trial for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X for the treatment of tumor bone metastasis; and CMAB015, a biosimilar candidate for secukinumab to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Mabpharm Limited Fundamentals Summary
|2181 fundamental statistics|
Is 2181 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|2181 income statement (TTM)|
|Cost of Revenue||CN¥10.52m|
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
|Earnings per share (EPS)||-0.047|
|Net Profit Margin||-272.90%|
How did 2181 perform over the long term?See historical performance and comparison